The Research Behind Veterans’ PTSD and Cannabis

Post-traumatic stress disorder (PTSD) is a common consequence of life-threatening experiences. Due to the frequent exposure to deprivation and trauma, veterans are at great risk of developing PTSD. Some of the associated symptoms are intrusive memories, hypervigilance, sleep disturbances, emotional numbing, and many others. These symptoms could become so severe that they impair relationships and quality of life. The two main management approaches are psychotherapy and the use of medications like selective serotonin reuptake inhibitors, but a good number of patients do not achieve remission using these methods, and many discontinue treatment because of side effects. These limitations have led to an interest in alternative therapies, like cannabis and its constituents tetrahydrocannabinol (THC) and cannabidiol (CBD).

Cannabis is widely used among U.S. veterans. Data from the U.S. Department of Veterans Affairs in 2019-2020 showed that 11.9% of veterans reported cannabis use, and the prevalence exceeded 20% among veterans aged 18–44. The legal landscape has also changed dramatically as over 30 U.S. states have allowed the use of medical cannabis for PTSD. Given these trends, it is important to examine the scientific evidence behind cannabis as a treatment for PTSD.

The Influence of Cannabis on PTSD

Cannabis interacts with the endocannabinoid system (ECS), which controls emotional memory through the CB1 and CB2 receptors. Experiments on preclinical models suggest that cannabinoids reduce fear and may enhance trauma-focused therapies. THC, alongside easing symptoms of PTSD, can have psychoactive effects which could affect cognition and pose risk of abuse, which necessitates thorough evaluation.

Evidence from Randomized Controlled Trials

Randomized-controlled trials (RCTs) are considered the gold standard for testing treatments. This is because RCTs allow scientists to see whether the improvements come from the treatment itself or just happened by chance or other factors. There are not many completed RCTs on the use of cannabis for managing PTSD. Below are some of the available RCTs.

Smoked cannabis versus placebo

The first randomized, placebo-controlled study of smoked cannabis in PTSD was conducted by the Multidisciplinary Association of Psychedelic Studies (MAPS). Fifty-four veterans were randomly assigned to different active cannabis preparations: high THC, high CBD, or a balanced THC/CBD versus a placebo with negligible cannabinoids.

Participants smoked freely for three weeks. The primary outcome (change in PTSD symptom severity) improved for all groups. The symptom severity scores declined by 10-20 points across all groups. Also, cannabis was well tolerated, though some participants reported anxiety, coughing, and dry mouth. However, there were no statistically significant differences between any type of cannabis and placebo.

A subsequent open-label phase (i.e., no placebo) suggested additional benefits, but the lack of a control group makes causal interpretation untenable.

Vaporized cannabis crossover study

In 2023, a Canadian pilot study examined vaporized cannabis using a double-blind, randomized crossover design with three arms: placebo cannabis, balanced THC/CBD, and THC-dominant cannabis. Only five participants completed the protocol due to under-recruitment. The researchers collapsed active arms and evaluated within-subject change. They found that Clinician Administered PTSD Scale scores declined from 39.0 to 30.7, and PTSD Checklist (PCL-5) scores dropped from 63.9 to 50.6. The small number of participants rendered the results inconclusive, though effects suggest possible benefits.

Pilot trial of cannabidiol with prolonged exposure therapy

The potential of cannabinoids to augment psychotherapy is also being investigated in current research. The goal of the U.S. Department of Defense-funded pilot RCT is to combine cannabidiol with prolonged exposure therapy. The rationale is that CBD’s anxiolytic effects may increase interest and participation in therapy and also improve memory.

The study assigns 24 participants to receive 250 mg of CBD (Epidiolex®) or a placebo twice daily for 18 days, alongside ten daily prolonged exposure sessions over two weeks. Outcomes include PTSD symptom severity (PCL-5), biological markers, and heart rate responses.

As a pilot, its primary aim is to assess feasibility, safety, and preliminary efficacy. Although the trial’s results are still pending, it will yield valuable information about cannabinoid use in conjunction with first-line psychotherapy.

Dronabinol for nightmares

Nightmares are symptoms of PTSD; they often persist despite therapy. A German multi-center RCT is investigating dronabinol (synthetic Δ9-THC) for PTSD-related nightmares versus a placebo.

The main outcome measure is the CAPS-IV B2 nightmare score. The protocol notes that cannabinoid agonists may offer relief from nightmares, even though the results are pending. The trial’s findings will help clarify whether THC analogues can reduce nightmare severity.

Results from Observational Studies

Prospective longitudinal study of cannabis users versus non-users

A 2022 prospective cohort study of 150 PTSD-affected adults who used cannabis showed a reduction in symptom severity and were 2.57 times more likely to undergo remission according to a survival analysis. Findings suggest a potential long-term benefit.

Cannabis-based medicinal products (CBMP) for PTSD

A UK observational study examined 238 adults with PTSD who were prescribed cannabis-based medicinal products (CBMPs). The average PTSD symptom scores of 116 participants with follow-up data at three months decreased from 58 to 47, which was a clinically significant decrease. Improvements were more pronounced for those who also had depression.

Cross-sectional research among veterans

A 2025 survey of Canadian veterans with trauma and chronic pain found no correlation between cannabis dosing variables and reduction in PTSD severity. Those in therapy or on prescribed cannabis had higher symptom levels, suggesting subjective relief without measurable improvement. Although many participants thought cannabis was beneficial, objective measurements did not reveal improved results. This suggests that cannabis may offer subjective relief.

Mobile app–based symptom tracking

The Strainprint™ app allowed Canadian study participants to record PTSD symptom ratings immediately before and after cannabis use. App data across 404 patients showed >50% immediate symptom reduction, but tolerance developed. Findings show temporary relief, but also raise concerns about dose escalation and long-term effect.

Potential Benefits and Risks for Veterans

Potential benefits

Short-term symptom relief: Observational studies and app-based tracking show that cannabis can provide rapid reductions in intrusions, flashbacks, anxiety, and hyperarousal.
Improved sleep and nightmares: Small studies of synthetic cannabinoids like nabilone and THC analogues report reductions in nightmares and improved quality of sleep. The ongoing dronabinol trial aims to test this effect rigorously.
Possible long-term benefit: The prospective cohort study found that cannabis users had greater reductions in PTSD symptoms over one year and were more likely to undergo remission.
Synergy with therapy: The hypothesised enhancement of extinction learning by CBD suggests that combining cannabinoids with trauma-focused therapy could improve outcomes. A pending trial hopes to confirm this possibility.

Potential risks

Cannabis use disorder and dependence: Veterans with PTSD are more than twice as likely to develop cannabis use disorder, and co-occurrence is linked to poorer mental health and functional outcomes.
Lack of robust evidence: The only completed RCT found no difference between cannabis and a placebo. Also, the crossover pilot had insufficient power to draw firm conclusions. Observational studies cannot establish causality and often involve self-selected patients using varying products at different doses.

Future Directions

Despite the absence of strong evidence regarding the use of cannabis in the management of PTSD, many study participants have noted subjective relief of their symptoms. Also, a 2025 update identified 11 ongoing studies which are expected to be finished within five years and hopefully, provide us with definitive answers. These studies are evaluating different cannabinoid products, dosages, routes of administration, and combinations with psychotherapy.

Conclusion

The research on cannabis for PTSD is in its early stages, but some veterans have reported short-term relief from intrusive memories, anxiety, and nightmares. It has also been noted that cannabinoids may complement psychotherapy and improve treatment engagement. Clinical trials have yet to confirm clear, long-term efficacy, and risks such as dependence and high-THC side effects require careful management.

For veterans who have not found relief with standard therapies, cannabis offers a promising alternative pathway that is already being widely embraced. Honest conversations between veterans and their clinicians or providers are important. This will inform strain selection, dosage, assess motives for use, screen for CUD, and provide harm-reduction education. When conventional therapy provides no relief, cannabis should be considered and with thoughtful integration, high-quality products, and ongoing research, cannabis will evolve from a source of subjective relief into a validated, evidence-based option for managing PTSD in veterans.